Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Solid Biosciences (SLDB) has disclosed Current Deferred Revenue for 3 consecutive years, with $6.2 million as the latest value for Q1 2022.

  • Quarterly Current Deferred Revenue fell 65.07% to $6.2 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Mar 2022, down 65.07% year-over-year, with the annual reading at $8.1 million for FY2021, 61.0% down from the prior year.
  • Current Deferred Revenue hit $6.2 million in Q1 2022 for Solid Biosciences, down from $8.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $20.7 million in Q4 2020 to a low of $6.2 million in Q1 2022.
  • Historically, Current Deferred Revenue has averaged $12.6 million across 3 years, with a median of $11.6 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 61.0% in 2021 and later plummeted 65.07% in 2022.
  • Year by year, Current Deferred Revenue stood at $20.7 million in 2020, then tumbled by 61.0% to $8.1 million in 2021, then fell by 23.64% to $6.2 million in 2022.
  • Business Quant data shows Current Deferred Revenue for SLDB at $6.2 million in Q1 2022, $8.1 million in Q4 2021, and $8.9 million in Q3 2021.